Federal Register Notice: FDA’s Transmissible Spongiform Encephalopathies Advisory Committee will meet 6/1, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave. Bldg. 31 Conference Center, the Great Room (Rm.1503), Silver Spring, MD. The Webcast will be available at the following link: https://collaboration.fda.gov/cbertseac/. The committee will meet in open session to hear update presentations on the following topics: (1) The variant Creutzfeldt-Jakob Disease (vCJD) situation worldwide and an update on the U.K.’s Transfusion Medicine Epidemiological Review; (2) vCJD in the U.S.; and (3) the bovine spongiform encephalopathy (BSE) situation worldwide and the U.S. Department of Agriculture’s regulatory approaches to reduce the risk of food-borne exposure of BSE. Following the update presentations the committee will hear presentations from FDA on current measures to reduce the risk of vCJD from transfusion in the U.S., and a mathematical model of the risk reduction achievable under the current and alternative geographically based donor deferral policies when implemented in conjunction with the use of leukocyte reduction of blood components. The committee will then discuss FDA’s geographically based donor deferral policies and other strategies, including leukocyte reduction of blood components, to reduce the risk of transfusion-transmitted vCJD. FDA will seek advice from the committee in developing future recommendations to reduce this risk. Contact Bryan Emery or Rosanna Harvey, (240) 402-8054 or (240) 402-8072. To view this notice, click here.